All participants were smokers or had either diabetes, cancer, depression, cardiovascular, respiratory, thyroid, or gastrointestinal disease and were receiving a DMT.
Natural history data from a subset of patients from the British Columbia MS database between 1980 to 1996 were used to create a continuous Markov model to model the projected course of disease in untreated people with RMS.
Researchers categorized samples into quintiles based on 25(OH)D3 concentrations in healthy controls.
Patients with progressive MS or secondary progressive MS who were receiving care at a single institution in France were prescribed 300 mg/day MD1003.
In patients with relapse-remitting multiple sclerosis, the initiation of oral disease-modifying therapies is associated with a lower relapse risk as well as a lower risk for disability progression.
Disability progression is slower among patients with pediatric-onset multiple sclerosis.
Patients with MS also have a higher risk for serious hospitalized-related infections compared with hospitalized patients without MS.
Investigators examine the effect of disease-modifying therapy on the rate of brain atrophy in patients with multiple sclerosis.
Study investigators assessed the changes in the Expanded Disability Status Scale and MS Severity Score after up to 7 courses of alemtuzumab.
The phase 3 PARADIGMS trial involving 215 pediatric patients demonstrated superior efficacy for fingolimod over interferon beta-1a.
Sign Up for Free e-newsletters
Check out what's trending
Neurology Advisor Articles
- Vitamin D3 Associated With Reductions in Migraine Days Among Migraineurs
- Hemicrania Continua: Diagnosis and Treatment
- Predicting Outcomes in Parkinson Disease: Utility of EEG
- Psychiatric Adverse Effects from Levetiracetam Linked to Certain Factors
- Prolonged Aura in Migraine Linked to More Sensory Symptoms